Last $63.59 USD
Change Today -0.51 / -0.80%
Volume 5.1M
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 8:04 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

710 Medtronic Parkway

Minneapolis, MN 55432

United States

Phone: 763-514-4000

Fax:

Medtronic, Inc. manufactures and sells device-based medical therapies. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries worldwide. Segments The company operates through three segments: Cardiac and Vascular Group; Restorative Therapies Group; and Diabetes Group. Cardiac and Vascular Group segment This segment includes Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart, and Endovascular. CRDM CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business. The following are the principal products offered by the company’s CRDM business: Implantable Cardiac Pacemakers (Pacemakers): A pacemaker is a battery-powered device implanted in the chest that delivers electrical impulses to treat bradycardia, a condition of abnormally slow heart rhythms, approximately 60 beats per minute, or unsteady heart rhythms that cause symptoms, such as dizziness, fainting, fatigue, and shortness of breath. The company’s new generation of pacemaker systems is compatible with certain magnetic resonance imaging (MRI) machines. These include the Advisa and Revo MRI SureScan models, which have received the United States (U.S.) Food and Drug Administration (U.S. FDA) approval; and the Advisa and Ensura MRI SureScan models, which have received Conformite Europeene (CE) Mark approval. The company also continues to market the Adapta product family, which includes the Adapta, Versa, and Sensia models. Implantable Cardioverter Defibrillators (ICDs): An ICD monitors the heart and delivers therapy when an abnormal heart rhythm, such as tachyarrhythmia, or rapid heart rhythm, occurs and leads to sudden cardiac arrest. The company’s new generation ICD is the Evera MRI SureScan, the first and only ICD system with CE Mark approval for full-body MRI scans. The Evera system is paired with the Sprint Quattro Secure lead, the only defibrillator lead with approximately 10 years of proven performance with active monitoring. In addition to Evera, devices in the ICD family include the Protecta XT/Protecta with SmartShock technology, including the Lead Integrity Alert, a technology designed to improve the detection of lead fractures, and the Cardia and Egida models. The company also continues to market the Secura, Virtuoso, and Maximo II devices. Implantable Cardiac Resynchronization Therapy (CRT) Devices: CRT devices are combined with defibrillation (CRT-D) or are pacing-only (CRT-P). These devices treat heart failure patients by altering the abnormal electrical sequence of cardiac contractions by sending tiny electrical impulses to the lower chambers of the heart to help them beat in a more synchronized fashion. The company’s new generation of CRT-Ds is the Viva/Brava family that features a new algorithm, called AdaptivCRT, which improves heart failure patients' response rate to CRT-D therapy, as compared to historical CRT trials, by preserving the patients' normal heart rhythms and continuously adapting to individual patient needs. Other features of the Viva/Brava portfolio include Ensure CRT, which works to improve CRT treatment, even during AF, SmartShock technology, increased battery longevity, and OptiVol 2.0 fluid status monitoring. In Europe, the company also has CE Mark approval for its Attain Performa quadripolar leads. Paired with its Viva/Brava Quad CRT-Ds, Attain Performa left-heart leads provide additional options for physicians as they navigate different patient anatomies, optimizing therapy based on the individual needs of heart failure patients. The company’s quadripolar technology is in the clinical evaluation process for the U.S. FDA approval. Its CRT-D devices also include the Protecta XT/Protecta with SmartShock technology. With respect to CRT-P, the company received CE Mark approval for its Viva CRT-P,

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $63.59 USD -0.51

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.11 USD -0.21
Allergan Inc/United States $165.56 USD +1.18
Astellas Pharma Inc ¥1,516 JPY +0.50
Becton Dickinson and Co $116.97 USD -0.56
Covidien PLC $88.26 USD -0.76
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 21.2x
Price/Sales 3.8x
Price/Book 3.3x
Price/Cash Flow 18.7x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.